Cargando…

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study

BACKGROUND: There are few real-world studies in which the efficacy of sequential crizotinib and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are compared with direct therapy of second-generation ALK TKI in ALK-positive advanced lung cancer. METHODS: Between Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jingwen, Zhou, Huan, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267910/ https://www.ncbi.nlm.nih.gov/pubmed/37324060 http://dx.doi.org/10.21037/jtd-22-1783

Ejemplares similares

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
por: Lu, Yue, et al.
Publicado: (2021)

Second- and third-generation ALK inhibitors for non-small cell lung cancer
por: Wu, Jingjing, et al.
Publicado: (2016)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
por: Carcereny, Enric, et al.
Publicado: (2021)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
por: Camidge, D. Ross, et al.
Publicado: (2020)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
por: Song, Zilan, et al.
Publicado: (2015)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
por: Gibson, Amanda J.W., et al.
Publicado: (2021)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
por: Zhao, Jiuzhou, et al.
Publicado: (2022)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
por: Kobayashi, Takayuki, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

ALK Inhibitors, a Pharmaceutical Perspective
por: Ardini, Elena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c8c8vftllbec3dv8pgbneisj6d